Hikma Pharmaceuticals
Hikma Pharmaceuticals
HIK
LSE
2009.90
GBX
-0.30%
About
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA).
The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 256.3K |
| Three Month Average Volume | 7.1M |
| High Low | |
| Fifty-Two Week High | 21.93 GBX |
| Fifty-Two Week Low | 17.11 GBX |
| Fifty-Two Week High Date | 04 Sep 2023 |
| Fifty-Two Week Low Date | 30 Nov 2023 |
| Price and Volume | |
| Current Price | 19.74 GBX |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.94% |
| Thirteen Week Relative Price Change | -0.35% |
| Twenty-Six Week Relative Price Change | -7.53% |
| Fifty-Two Week Relative Price Change | -19.07% |
| Year-to-Date Relative Price Change | 2.24% |
| Price Change | |
| One Day Price Change | -0.45% |
| Thirteen Week Price Change | 0.77% |
| Twenty-Six Week Price Change | 1.18% |
| Five Day Price Change | -1.99% |
| Fifty-Two Week Price Change | -9.16% |
| Year-to-Date Price Change | 10.34% |
| Month-to-Date Price Change | -0.45% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.56102 GBX |
| Book Value Per Share (Most Recent Quarter) | 7.86374 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.77707 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.10043 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 2.75249 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 9.83262 GBX |
| Revenue Per Share (Trailing Twelve Months) | 10.27753 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0.55203 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0.60292 GBX |
| Dividend Per Share (5 Year) | 0.42774 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.64981 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.96957 GBX |
| Normalized (Last Fiscal Year) | 1.68266 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.65424 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.979 GBX |
| Including Extraordinary Items (Last Fiscal Year) | 0.64981 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | 0.96957 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.78775 GBX |
| Cash Per Share (Most Recent Quarter) | 0.89439 GBX |
| Cash Flow Per Share (Last Fiscal Year) | 1.30988 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | 1.63855 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.74944 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 8 |
| Cash Flow Revenue (Trailing Twelve Months) | 7 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 12.16% |
| Pretax Margin (Last Fiscal Year) | 9.77% |
| Pretax Margin (5 Year) | 16.87% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 48.94% |
| Gross Margin (Trailing Twelve Months) | 47.40% |
| Gross Margin (5 Year) | 50.29% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 12.59% |
| Operating Margin (Trailing Twelve Months) | 14.78% |
| Operating Margin (5 Year) | 19.26% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 6.68% |
| Net Profit Margin (Trailing Twelve Months) | 9.61% |
| Net Profit Margin (5 Year) | 13.77% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 7.34% |
| Tangible Book Value (5 Year) | 3.62% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | 5.22% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 9.95% |
| Revenue Growth (3 Year) | 6.73% |
| Revenue Change (Trailing Twelve Months) | 10.47% |
| Revenue Per Share Growth | 8.55% |
| Revenue Growth (5 Year) | 7.09% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 7.97% |
| Total Debt (5 Year) | 13.33% |
| Dividends | |
| Dividend Growth (3 Year) | 12.74% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 71.16% |
| EPS Change (Trailing Twelve Months) | 93.85% |
| EPS Growth (3 Year) | -6.02% |
| EPS Growth (5 Year) | -22.15% |
| EBITDA | |
| EBITDA (5 Year) | 7.44% |
| EBITDA (5 Year Interim) | 7.04% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -13.42% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 5 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 22 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 26 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 772.7M |
| Net Debt (Last Fiscal Year) | 731.6M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 2 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 20 |
| PE Normalized (Last Fiscal Year) | 12 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 19 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 37 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 13 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 20 |
| Dividends | |
| Dividend Yield (5 Year) | 2.12% |
| Dividend Yield | 3.11% |
| Current Dividend Yield | 3.05% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 47 |
| Long Term Debt to Equity (Most Recent Quarter) | 46 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 83.68% |
| Payout Ratio (Trailing Twelve Months) | 61.40% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 160 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 58 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 203.1M |
| Free Cash Flow (Trailing Twelve Months) | 167.3M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 9 |
| Net Interest Coverage (Trailing Twelve Months) | 8 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 54 |
| Total Debt to Equity (Most Recent Quarter) | 56 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 4.20% |
| Return on Assets (Trailing Twelve Months) | 6.13% |
| Return on Assets (5 Year) | 8.19% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 8.77% |
| Return on Equity (Trailing Twelve Months) | 12.74% |
| Return on Equity (5 Year) | 15.92% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 5.72% |
| Return on Investment (Trailing Twelve Months) | 8.47% |
| Return on Investment (5 Year) | 11.30% |